Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,166 across all filing types
Latest filing 2025-09-30 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product (Rivaroxaban for Oral Suspension). It is addressed to stock exchanges and regulatory bodies under SEBI regulations, indicating it is a regulatory disclosure. The content is a brief announcement of a corporate event (FDA approval) rather than a financial report, earnings release, or detailed investor presentation. The document length is 4120 characters, which is relatively short and consistent with a press release or regulatory announcement. There is no financial data, no management discussion, no voting results, no audit information, or other report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-09-30 English
Lupin Receives Approval from U.S. FDA for Rivaroxaban for Oral Suspension.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product (Rivaroxaban for Oral Suspension). It is addressed to stock exchanges and regulatory bodies under SEBI regulations, indicating it is a regulatory disclosure. The content is an announcement of an event (FDA approval) rather than a financial report, earnings release, or management discussion. The document length is 4120 characters, which is relatively short and consistent with a press release or regulatory announcement. There is no financial data, no detailed financial statements, no management analysis, or other report content. Therefore, this document fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories like earnings release, capital update, or management information.
2025-09-30 English
Retirement of Senior Management Personnel
Board/Management Information Classification · 95% confidence The document is a formal disclosure pursuant to Regulation 30 of the SEBI Listing Regulations regarding the retirement of a senior management personnel, Mr. Rajendra Chunodkar, President - Manufacturing Operations. It includes details required under SEBI regulations about the cessation of employment. There is no financial data, earnings information, or report attached. The content focuses on management personnel change, which fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or certification. Therefore, the correct classification is MANG with high confidence.
2025-09-30 English
Retirement
Board/Management Information Classification · 100% confidence The document is a formal disclosure pursuant to Regulation 30 of the SEBI Listing Regulations regarding the retirement of a senior management personnel, Mr. Rajendra Chunodkar. It provides details about the cessation of employment effective September 30, 2025, and includes an annexure with required particulars. There is no financial data, no report attached or referenced as published, and the content focuses solely on management personnel change. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management.
2025-09-30 English
Nanomi B.V., the Netherlands, a wholly owned subsidiary of the Company in Netherlands, has entered into a definitive agreement to acquire the entire share capital of VISUfarma B.V., headquartered ....
M&A Activity Classification · 95% confidence The document is a detailed announcement from Lupin Limited regarding the acquisition of VISUfarma B.V. It includes extensive information about the target company, financial details, strategic rationale, regulatory approvals, and transaction terms. The document references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosure of material events. The content is focused on the acquisition transaction and its impact, including financial figures and strategic context, rather than being a full financial report or earnings release. It is not a brief press release but a comprehensive disclosure about a merger and acquisition event. Therefore, the document fits best under the category of M&A Activity (Code: TAR), which covers announcements and documents related to merger proposals or takeover bids.
2025-09-29 English
Acquisition
M&A Activity Classification · 95% confidence The document is a detailed announcement by Lupin Limited about its wholly owned subsidiary Nanomi B.V. entering into a definitive agreement to acquire VISUfarma B.V., a specialty pharmaceutical company. The text includes extensive information about the acquisition such as the target entity details, financials, strategic rationale, regulatory approvals, consideration, and expected completion timeline. It also contains a press release with quotes from company executives and advisors. The document is clearly an acquisition announcement with comprehensive disclosure as required under SEBI Listing Regulations, including financial and strategic details of the transaction. This fits the definition of M&A Activity (Code: TAR), which covers announcements and documents related to merger proposals or takeover bids. The document is not a full merger filing (MA), nor a simple regulatory filing or press release without detail. It is not an earnings release, annual report, or other financial report. Therefore, the appropriate classification is M&A Activity (TAR) with high confidence.
2025-09-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.